After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant ...
Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...
Novartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it ...
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease, breaking the ...
Takeda is setting the stage for a sweeping new round of restructuring, aiming to streamline operations to bankroll upcoming ...
Over the last seven months, Boehringer Ingelheim has gained approvals and label expansions in the U.S. for two of its newest ...
Healthcare professionals aren’t immune to societal shifts toward gathering information from artificial intelligence tools, social media and streaming content, opening up new opportunities for healt | ...
UCB plans to build a $2 billion manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the ...
A high-profile drug fraud case that could see the pharmaceutical industry thrown into the Racketeer Influenced and Corrupt ...
Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to ...
Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results